Skip to main content Accessibility help
×
Home

Nutritional management of hyperapoB

  • Valérie Lamantia (a1) (a2) (a3), Allan Sniderman (a4) and May Faraj (a1) (a2) (a3)

Abstract

Plasma apoB is a more accurate marker of the risk of CVD and type 2 diabetes (T2D) than LDL-cholesterol; however, nutritional reviews targeting apoB are scarce. Here we reviewed eighty-seven nutritional studies and present conclusions in order of strength of evidence. Plasma apoB was reduced in all studies that induced weight loss of 6–12 % using hypoenergetic diets (seven studies; 5440–7110 kJ/d; 1300–1700 kcal/d; 34–50 % carbohydrates; 27–39 % fat; 18–24 % protein). When macronutrients were compared in isoenergetic diets (eleven studies including eight randomised controlled trials (RCT); n 1189), the diets that reduced plasma apoB were composed of 26–51 % carbohydrates, 26–46 % fat, 11–32 % protein, 10–27 % MUFA, 5–14 % PUFA and 7–13 % SFA. Replacement of carbohydrate by MUFA, not SFA, decreased plasma apoB. Moreover, dietary enriching with n-3 fatty acids (FA) (from fish: 1·1–1·7 g/d or supplementation: 3·2–3·4 g/d EPA/DHA or 4 g/d EPA), psyllium (about 8–20 g/d), phytosterols (about 2–4 g/d) or nuts (30–75 g/d) also decreased plasma apoB, mostly in hyperlipidaemic subjects. While high intake of trans-FA (4·3–9·1 %) increased plasma apoB, it is unlikely that these amounts represent usual consumption. Inconsistent data existed on the effect of soya proteins (25–30 g/d), while the positive association of alcohol consumption with low plasma apoB was reported in cross-sectional studies only. Five isoenergetic studies using Mediterranean diets (including two RCT; 823 subjects) reported a decrease of plasma apoB, while weaker evidence existed for Dietary Approaches to Stop Hypertension (DASH), vegetarian, Nordic and Palaeolithic diets. We recommend using a Mediterranean dietary pattern, which also encompasses the dietary components reported to reduce plasma apoB, to target hyperapoB and reduce the risks of CVD and T2D.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Nutritional management of hyperapoB
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Nutritional management of hyperapoB
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Nutritional management of hyperapoB
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: Dr May Faraj, fax +1 514 987 5645, email may.faraj@umontreal.ca

References

Hide All
1. Anderson, TJ, Gregoire, J, Hegele, RA, et al. (2013) 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29, 151167.
2. Lewis, GF, Uffelman, KD, Szeto, LW, et al. (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42, 833842.
3. Malmstrom, R, Packard, CJ, Caslake, M, et al. (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40, 454462.
4. Ginsberg, HN, Zhang, YL & Hernandez-Ono, A (2005) Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36, 232240.
5. Sniderman, AD, St-Pierre, AC, Cantin, B, et al. (2003) Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91, 11731177.
6. Sniderman, A, Shapiro, S, Marpole, D, et al. (1980) Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A 77, 604608.
7. Connelly, PW, Poapst, M, Davignon, J, et al. (1999) Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol 15, 409418.
8. Holewijn, S, Sniderman, AD, den Heijer, M, et al. (2011) Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest 41, 423433.
9. Sniderman, AD, Williams, K, Contois, JH, et al. (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4, 337345.
10. Contois, JH, McConnell, JP, Sethi, AA, et al. (2009) Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 55, 407419.
11. Genest, J, McPherson, R, Frohlich, J, et al. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 25, 567579.
12. Anderson, TJ, Gregoire, J, Hegele, RA, et al. (2014) Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol 30, 377380.
13. Catapano, AL, Reiner, Z, De Backer, G, et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217, 346.
14. Stone, NJ, Robinson, JG, Lichtenstein, AH, et al. (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63, 28892934.
15. Pencina, MJ, D’Agostino, RB, Zdrojewski, T, et al. (2015) Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol 22, 13211327.
16. Sniderman, AD, Lamarche, B, Contois, JH, et al. (2014) Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Curr Opin Lipidol 25, 461467.
17. Williams, KJ & Tabas, I (2005) Lipoprotein retention – and clues for atheroma regression. Arterioscler Thromb Vasc Biol 25, 15361540.
18. Fan, J & Watanabe, T (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10, 6371.
19. Faraj, M, Messier, L, Bastard, JP, et al. (2006) Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 49, 16371646.
20. Ridker, PM, Rifai, N, Rose, L, et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347, 15571565.
21. Schlitt, A, Blankenberg, S, Bickel, C, et al. (2005) Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 102, 477485.
22. Bermudez, EA, Rifai, N, Buring, J, et al. (2002) Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22, 16681673.
23. Wassef, H, Bissonnette, S, Saint-Pierre, N, et al. (2015) The apoB-to-PCSK9 ratio: a new index for metabolic risk in humans. J Clin Lipidol 9, 664675.
24. Bissonnette, S, Salem, H, Wassef, H, et al. (2013) Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue. J Lipid Res 54, 14661476.
25. Bissonnette, S, Saint-Pierre, N, Lamantia, V, et al. (2015) Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans. Nutr Diabetes 5, e180.
26. Onat, A, Can, G, Hergenc, G, et al. (2007) Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 31, 11191125.
27. Ley, SH, Harris, SB, Connelly, PW, et al. (2010) Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 56, 666670.
28. Salomaa, V, Havulinna, A, Saarela, O, et al. (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5, e10100.
29. Hwang, YC, Ahn, HY, Park, SW, et al. (2014) Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetol 51, 941946.
30. Lamarche, B & Couture, P (2015) Dietary fatty acids, dietary patterns, and lipoprotein metabolism. Curr Opin Lipidol 26, 4247.
31. Ooi, EM, Ng, TW, Watts, GF, et al. (2013) Dietary fatty acids and lipoprotein metabolism: new insights and updates. Curr Opin Lipidol 24, 192197.
32. Chan, DC, Barrett, PH & Watts, GF (2014) The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res Clin Endocrinol Metab 28, 369385.
33. Gammon, CS, Minihane, AM, Kruger, R, et al. (2014) TaqIB polymorphism in the cholesteryl ester transfer protein (CETP) gene influences lipid responses to the consumption of kiwifruit in hypercholesterolaemic men. Br J Nutr 111, 10771084.
34. Gammon, CS, Kruger, R, Minihane, AM, et al. (2013) Kiwifruit consumption favourably affects plasma lipids in a randomised controlled trial in hypercholesterolaemic men. Br J Nutr 109, 22082218.
35. Hu, M, Li, Z & Fang, DZ (2012) A high-carbohydrate diet effects on the A allele of hepatic lipase polymorphism on the apoB100/apoAI ratio in young Chinese males. Adv Clin Exp Med 21, 751757.
36. Curti, ML, Rogero, MM, Baltar, VT, et al. (2013) FTO T/A and peroxisome proliferator-activated receptor-γ Pro12Ala polymorphisms but not ApoA1 -75 are associated with better response to lifestyle intervention in Brazilians at high cardiometabolic risk. Metab Syndr Relat Disord 11, 169176.
37. Feinman, RD, Pogozelski, WK, Astrup, A, et al. (2015) Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition 31, 113.
38. Tuomilehto, J, Lindstrom, J, Eriksson, JG, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344, 13431350.
39. Dattilo, AM & Kris-Etherton, PM (1992) Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56, 320328.
40. Poobalan, A, Aucott, L, Smith, WC, et al. (2004) Effects of weight loss in overweight/obese individuals and long-term lipid outcomes – a systematic review. Obes Rev 5, 4350.
41. Chan, DC, Watts, GF, Gan, SK, et al. (2010) Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33, 11341139.
42. Faraj, M, Lavoie, ME, Messier, L, et al. (2010) Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: a MONET study. Atherosclerosis 211, 682688.
43. Ng, TW, Watts, GF, Barrett, PH, et al. (2007) Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 30, 29452950.
44. de la Iglesia, R, Lopez-Legarrea, P, Crujeiras, AB, et al. (2014) Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf) 81, 306311.
45. Valente, EA, Sheehy, ME, Avila, JJ, et al. (2011) The effect of the addition of resistance training to a dietary education intervention on apolipoproteins and diet quality in overweight and obese older adults. Clin Interv Aging 6, 235241.
46. Vasudevan, M, Tchoua, U, Gillard, BK, et al. (2013) Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol 7, 661670.
47. Pelletier-Beaumont, E, Arsenault, BJ, Almeras, N, et al. (2012) Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. Atherosclerosis 221, 577582.
48. Lavoie, ME, Faraj, M, Strychar, I, et al. (2013) Synergistic associations of physical activity and diet quality on cardiometabolic risk factors in overweight and obese postmenopausal women. Br J Nutr 109, 605614.
49. Haghighatdoost, F, Sarrafzadegan, N, Mohammadifard, N, et al. (2013) Healthy eating index and cardiovascular risk factors among Iranians. J Am Coll Nutr 32, 111121.
50. Health Canada (2011) Eating Well with Canada’s Food Guide: A Resource for Educators and Communicators. Ottawa: Health Canada.
51. Hellwig, JP, Otten, JJ, Meyers, LD, et al. (2006) Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC: National Academies Press.
52. United States Department of Agriculture and United States Deparment of Health and Human Services (2010) Dietary Guidelines for Americans 2010, 7th ed. Washington, DC: United States Government Printing Office.
53. Parks, EJ (2001) Effect of dietary carbohydrate on triglyceride metabolism in humans. J Nutr 131, 2772s2774s.
54. Lichtenstein, AH (2006) Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res 47, 16611667.
55. Schwingshackl, L & Hoffmann, G (2013) Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis. J Acad Nutr Diet 113, 16401661.
56. Shin, MJ, Blanche, PJ, Rawlings, RS, et al. (2007) Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins. Am J Clin Nutr 85, 15271532.
57. Parks, EJ & Hellerstein, MK (2000) Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 71, 412433.
58. Sacks, FM (2006) The apolipoprotein story. Atheroscler Suppl 7, 2327.
59. Krauss, RM, Blanche, PJ, Rawlings, RS, et al. (2006) Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr 83, 10251031; quiz 1205.
60. Labonte, ME, Jenkins, DJ, Lewis, GF, et al. (2013) Adding MUFA to a dietary portfolio of cholesterol-lowering foods reduces apoAI fractional catabolic rate in subjects with dyslipidaemia. Br J Nutr 110, 426436.
61. Faghihnia, N, Tsimikas, S, Miller, ER, et al. (2010) Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 51, 33243330.
62. Mangravite, LM, Chiu, S, Wojnoonski, K, et al. (2011) Changes in atherogenic dyslipidemia induced by carbohydrate restriction in men are dependent on dietary protein source. J Nutr 141, 21802185.
63. Mercanligil, SM, Arslan, P, Alasalvar, C, et al. (2007) Effects of hazelnut-enriched diet on plasma cholesterol and lipoprotein profiles in hypercholesterolemic adult men. Eur J Clin Nutr 61, 212220.
64. Brinkworth, GD, Noakes, M, Buckley, JD, et al. (2009) Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am J Clin Nutr 90, 2332.
65. Tay, J, Brinkworth, GD, Noakes, M, et al. (2008) Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects. J Am Coll Cardiol 51, 5967.
66. Miller, M, Beach, V, Sorkin, JD, et al. (2009) Comparative effects of three popular diets on lipids, endothelial function, and C-reactive protein during weight maintenance. J Am Diet Assoc 109, 713717.
67. Keogh, JB, Grieger, JA, Noakes, M, et al. (2005) Flow-mediated dilatation is impaired by a high-saturated fat diet but not by a high-carbohydrate diet. Arterioscler Thromb Vasc Biol 25, 12741279.
68. Johnson, RK, Appel, LJ, Brands, M, et al. (2009) Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 120, 10111020.
69. Swarbrick, MM, Stanhope, KL, Elliott, SS, et al. (2008) Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women. Br J Nutr 100, 947952.
70. Semenkovich, CF (2006) Insulin resistance and atherosclerosis. J Clin Invest 116, 18131822.
71. Stanhope, KL, Bremer, AA, Medici, V, et al. (2011) Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 96, E1596E1605.
72. Lattimer, JM & Haub, MD (2010) Effects of dietary fiber and its components on metabolic health. Nutrients 2, 12661289.
73. Theuwissen, E & Mensink, RP (2008) Water-soluble dietary fibers and cardiovascular disease. Physiol Behav 94, 285292.
74. Fernandez, ML, Vergara-Jimenez, M, Conde, K, et al. (1997) Regulation of apolipoprotein B-containing lipoproteins by dietary soluble fiber in guinea pigs. Am J Clin Nutr 65, 814822.
75. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 31433421.
76. Shrestha, S, Volek, JS, Udani, J, et al. (2006) A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr 136, 24922497.
77. Moreyra, AE, Wilson, AC & Koraym, A (2005) Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 165, 11611166.
78. Sola, R, Valls, RM, Godas, G, et al. (2012) Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trial. PLOS ONE 7, e31103.
79. Comerford, KB, Artiss, JD, Jen, KL, et al. (2011) The beneficial effects of α-cyclodextrin on blood lipids and weight loss in healthy humans. Obesity (Silver Spring) 19, 12001204.
80. Food and Agriculture Organization of the United Nations (2010) Fats and Fatty Acids in Human Nutrition: Report of an Expert Consultation, no. 9789251067338]. Geneva: Food and Agriculture Organization of the United Nations.
81. Mozaffarian, D & Clarke, R (2009) Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 63, Suppl. 2, S22S33.
82. Jebb, SA, Lovegrove, JA, Griffin, BA, et al. (2010) Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 92, 748758.
83. Berglund, L, Lefevre, M, Ginsberg, HN, et al. (2007) Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr 86, 16111620.
84. Allman-Farinelli, MA, Gomes, K, Favaloro, EJ, et al. (2005) A diet rich in high-oleic-acid sunflower oil favorably alters low-density lipoprotein cholesterol, triglycerides, and factor VII coagulant activity. J Am Diet Assoc 105, 10711079.
85. van Dijk, SJ, Feskens, EJ, Bos, MB, et al. (2012) Consumption of a high monounsaturated fat diet reduces oxidative phosphorylation gene expression in peripheral blood mononuclear cells of abdominally overweight men and women. J Nutr 142, 12191225.
86. Bos, MB, de Vries, JH, Feskens, EJ, et al. (2010) Effect of a high monounsaturated fatty acids diet and a Mediterranean diet on serum lipids and insulin sensitivity in adults with mild abdominal obesity. Nutr Metab Cardiovasc Dis 20, 591598.
87. Binkoski, AE, Kris-Etherton, PM, Wilson, TA, et al. (2005) Balance of unsaturated fatty acids is important to a cholesterol-lowering diet: comparison of mid-oleic sunflower oil and olive oil on cardiovascular disease risk factors. J Am Diet Assoc 105, 10801086.
88. Lee, JY, Zhao, L & Hwang, DH (2010) Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev 68, 3861.
89. Flock, MR, Green, MH & Kris-Etherton, PM (2011) Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol. Adv Nutr 2, 261274.
90. Schwartz, EA, Zhang, WY, Karnik, SK, et al. (2010) Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 30, 802808.
91. Chait, A & Kim, F (2010) Saturated fatty acids and inflammation: who pays the toll? Arterioscler Thromb Vasc Biol 30, 692693.
92. Mustad, VA, Etherton, TD, Cooper, AD, et al. (1997) Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women. J Lipid Res 38, 459468.
93. Santos, S, Oliveira, A & Lopes, C (2013) Systematic review of saturated fatty acids on inflammation and circulating levels of adipokines. Nutr Res 33, 687695.
94. Teng, KT, Chang, CY, Chang, LF, et al. (2014) Modulation of obesity-induced inflammation by dietary fats: mechanisms and clinical evidence. Nutr J 13, 12.
95. Cave, MC, Hurt, RT, Frazier, TH, et al. (2008) Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 23, 1634.
96. Bays, HE, Tighe, AP, Sadovsky, R, et al. (2008) Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 6, 391409.
97. Kris-Etherton, PM, Harris, WS & Appel, LJ (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 27472757.
98. Bays, HE, Ballantyne, CM, Kastelein, JJ, et al. (2011) Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 108, 682690.
99. Davidson, MH, Stein, EA, Bays, HE, et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29, 13541367.
100. Bays, HE, McKenney, J, Maki, KC, et al. (2010) Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 85, 122128.
101. Zhang, J, Wang, C, Li, L, et al. (2012) Dietary inclusion of salmon, herring and pompano as oily fish reduces CVD risk markers in dyslipidaemic middle-aged and elderly Chinese women. Br J Nutr 108, 14551465.
102. Lee, SP, Dart, AM, Walker, KZ, et al. (2012) Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. Br J Nutr 108, 12801285.
103. Wong, AT, Chan, DC, Ooi, EM, et al. (2013) Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. Clin Sci (Lond) 125, 4551.
104. Wong, AT, Chan, DC, Barrett, PH, et al. (2014) Effect of omega-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab 99, E1427E1435.
105. Ooi, EM, Lichtenstein, AH, Millar, JS, et al. (2012) Effects of therapeutic lifestyle change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J Lipid Res 53, 19581967.
106. Forster, LF, Stewart, G, Bedford, D, et al. (2002) Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164, 129145.
107. Karalis, DG, Ross, AM, Vacari, RM, et al. (2002) Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 89, 667671.
108. Watts, GF, Chan, DC, Ooi, EM, et al. (2006) Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies. Clin Exp Pharmacol Physiol 33, 877882.
109. Pan, M, Maitin, V, Parathath, S, et al. (2008) Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc Natl Acad Sci U S A 105, 58625867.
110. Pan, A, Chen, M, Chowdhury, R, et al. (2012) α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 96, 12621273.
111. Institute of Medicine (2002) Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids . Washington, DC: National Academies Press.
112. Dodin, S, Cunnane, SC, Masse, B, et al. (2008) Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutrition 24, 2330.
113. Dodin, S, Lemay, A, Jacques, H, et al. (2005) The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 90, 13901397.
114. Brenna, JT, Salem, N Jr., Sinclair, AJ, et al. (2009) α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 80, 8591.
115. Vega-López, S, Matthan, NR, Ausman, LM, et al. (2009) Substitution of vegetable oil for a partially-hydrogenated fat favorably alters cardiovascular disease risk factors in moderately hypercholesterolemic postmenopausal women. Atherosclerosis 207, 208212.
116. Wanders, AJ, Brouwer, IA, Siebelink, E, et al. (2010) Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. PLoS ONE 5, e9000.
117. Martin, CA, Milinsk, MC, Visentainer, JV, et al. (2007) Trans fatty acid-forming processes in foods: a review. An Acad Bras Cienc 79, 343350.
118. Brouwer, IA, Wanders, AJ & Katan, MB (2013) Trans fatty acids and cardiovascular health: research completed? Eur J Clin Nutr 67, 541547.
119. Chardigny, JM, Destaillats, F, Malpuech-Brugere, C, et al. (2008) Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study. Am J Clin Nutr 87, 558566.
120. Health Canada (2009) General Questions and Answers on Trans Fat. http://www.hc-sc.gc.ca/fn-an/nutrition/gras-trans-fats/tfa-age_question-eng.php (accessed February 2016).
121. United States Food and Drug Administration (2015) The FDA takes step to remove artificial trans fats in processed foods. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm451237.htm (accessed June 2016).
122. Rouis, M, Dugi, KA, Previato, L, et al. (1997) Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol 17, 14001406.
123. Tremblay, AJ, Lamarche, B, Labonte, ME, et al. (2014) Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Am J Clin Nutr 99, 5461.
124. Bohl, M, Bjornshave, A, Rasmussen, KV, et al. (2015) Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. Am J Clin Nutr 101, 870878.
125. Rego Costa, AC, Rosado, EL & Soares-Mota, M (2012) Influence of the dietary intake of medium chain triglycerides on body composition, energy expenditure and satiety: a systematic review. Nutr Hosp 27, 103108.
126. Eckel, RH, Jakicic, JM, Ard, JD, et al. (2014) 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S76S99.
127. Cesar, TB, Oliveira, MR, Mesquita, CH, et al. (2006) High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. J Nutr 136, 971976.
128. Pearce, KL, Clifton, PM & Noakes, M (2011) Egg consumption as part of an energy-restricted high-protein diet improves blood lipid and blood glucose profiles in individuals with type 2 diabetes. Br J Nutr 105, 584592.
129. AbuMweis, SS, Marinangeli, CP, Frohlich, J, et al. (2014) Implementing phytosterols into medical practice as a cholesterol-lowering strategy: overview of efficacy, effectiveness, and safety. Can J Cardiol 30, 12251232.
130. Demonty, I, Ras, RT, van der Knaap, HC, et al. (2009) Continuous dose–response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 139, 271284.
131. Abumweis, SS, Barake, R & Jones, PJ (2008) Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 52, 10.3402/fnr.v52i0.1811.
132. Klingberg, S, Andersson, H, Mulligan, A, et al. (2008) Food sources of plant sterols in the EPIC Norfolk population. Eur J Clin Nutr 62, 695703.
133. Sialvera, TE, Pounis, GD, Koutelidakis, AE, et al. (2012) Phytosterols supplementation decreases plasma small and dense LDL levels in metabolic syndrome patients on a Westernized type diet. Nutr Metab Cardiovasc Dis 22, 843848.
134. Anderson, JW, Johnstone, BM & Cook-Newell, ME (1995) Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333, 276282.
135. Anonymous (1999) Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist 64, 5700057733.
136. Potter, SM (1995) Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 125, 606s611s.
137. Baum, JA, Teng, H, Erdman, JW Jr, et al. (1998) Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 68, 545551.
138. Campbell, SC, Khalil, DA, Payton, ME, et al. (2010) One-year soy protein supplementation does not improve lipid profile in postmenopausal women. Menopause 17, 587593.
139. Maki, KC, Butteiger, DN, Rains, TM, et al. (2010) Effects of soy protein on lipoprotein lipids and fecal bile acid excretion in men and women with moderate hypercholesterolemia. J Clin Lipidol 4, 531542.
140. Chen, ST, Ferng, SH, Yang, CS, et al. (2005) Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis 46, 10991106.
141. Chen, ST, Chen, JR, Yang, CS, et al. (2006) Effect of soya protein on serum lipid profile and lipoprotein concentrations in patients undergoing hypercholesterolaemic haemodialysis. Br J Nutr 95, 366371.
142. Fanti, P, Sawaya, BP, Custer, LJ, et al. (1999) Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J Am Soc Nephrol 10, 864871.
143. Santo, AS, Santo, AM, Browne, RW, et al. (2010) Postprandial lipemia detects the effect of soy protein on cardiovascular disease risk compared with the fasting lipid profile. Lipids 45, 11271138.
144. Santo, AS, Cunningham, AM, Alhassan, S, et al. (2008) NMR analysis of lipoprotein particle size does not increase sensitivity to the effect of soy protein on CVD risk when compared with the traditional lipid profile. Appl Physiol Nutr Metab 33, 489500.
145. McVeigh, BL, Dillingham, BL, Lampe, JW, et al. (2006) Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Am J Clin Nutr 83, 244251.
146. Pipe, EA, Gobert, CP, Capes, SE, et al. (2009) Soy protein reduces serum LDL cholesterol and the LDL cholesterol:HDL cholesterol and apolipoprotein B:apolipoprotein A-I ratios in adults with type 2 diabetes. J Nutr 139, 17001706.
147. Kwak, JH, Ahn, CW, Park, SH, et al. (2012) Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study. Food Funct 3, 10191024.
148. Axelson, M, Kirk, DN, Farrant, RD, et al. (1982) The identification of the weak oestrogen equol [7-hydroxy-3-(4’-hydroxyphenyl)chroman] in human urine. Biochem J 201, 353357.
149. Setchell, KD, Brown, NM & Lydeking-Olsen, E (2002) The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 35773584.
150. Barton, M (2013) Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol 24, 214220.
151. Frota, KMG, dos Santos, RD, Ribeiro, VQ, et al. (2015) Cowpea protein reduces LDL-cholesterol and apolipoprotein B concentrations, but does not improve biomarkers of inflammation or endothelial dysfunction in adults with moderate hypercholesterolemia. Nutr Hosp 31, 16111619.
152. Pereira, PC (2014) Milk nutritional composition and its role in human health. Nutrition 30, 619627.
153. Butt, P, Beirness, D, Gliksman, L, et al. (2011) Alcohol and Health in Canada: A Summary of Evidence and Guidelines for Low Risk Drinking. Ottawa, ON: Canadian Centre on Substance Abuse.
154. Volcik, KA, Ballantyne, CM, Fuchs, FD, et al. (2008) Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study. Ann Epidemiol 18, 101107.
155. Tognon, G, Berg, C, Mehlig, K, et al. (2012) Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake. PLOS ONE 7, e40878.
156. Liangpunsakul, S, Qi, R, Crabb, DW, et al. (2010) Relationship between alcohol drinking and aspartate aminotransferase:alanine aminotransferase (AST:ALT) ratio, mean corpuscular volume (MCV), γ-glutamyl transpeptidase (GGT), and apolipoprotein A1 and B in the U.S. population. J Stud Alcohol Drugs 71, 249252.
157. Simonsson, M, Schmidt, C, Sigurdadottir, V, et al. (2007) Life style habits such as alcohol consumption and physical activity in relation to serum apoB/apoA-I ratio amongst 64-year-old women with varying degrees of glucose tolerance. J Intern Med 262, 537544.
158. Kawata, S, Fukuda, K, Inui, Y, et al. (1993) Molecular biology in development of fatty liver – regulation of apolipoprotein B synthesis [article in Japanese]. Nihon Rinsho 51, 414422.
159. Klop, B, do Rego, AT & Cabezas, MC (2013) Alcohol and plasma triglycerides. Curr Opin Lipidol 24, 321326.
160. Naissides, M, Mamo, JC, James, AP, et al. (2006) The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. Atherosclerosis 185, 438445.
161. Pal, S, Ho, N, Santos, C, et al. (2003) Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 133, 700706.
162. Pal, S, Ho, SS & Takechi, R (2005) Red wine polyphenolics suppress the secretion of ApoB48 from human intestinal CaCo-2 cells. J Agric Food Chem 53, 27672772.
163. Tomé-Carneiro, J, Gonzálvez, M, Larrosa, M, et al. (2012) Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 56, 810821.
164. Martini, LA, Catania, AS & Ferreira, SR (2010) Role of vitamins and minerals in prevention and management of type 2 diabetes mellitus. Nutr Rev 68, 341354.
165. Montonen, J, Knekt, P, Jarvinen, R, et al. (2004) Dietary antioxidant intake and risk of type 2 diabetes. Diabetes Care 27, 362366.
166. Al-Daghri, NM, Alkharfy, KM, Al-Saleh, Y, et al. (2012) Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metabolism 61, 661666.
167. McGill, AT, Stewart, JM, Lithander, FE, et al. (2008) Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 7, 4.
168. Czernichow, S, Vergnaud, AC, Galan, P, et al. (2009) Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am J Clin Nutr 90, 329335.
169. Ros, E & Mataix, J (2006) Fatty acid composition of nuts – implications for cardiovascular health. Br J Nutr 96, Suppl. 2, S29S35.
170. Chen, CY & Blumberg, JB (2008) Phytochemical composition of nuts. Asia Pac J Clin Nutr 17, Suppl. 1, 329332.
171. Bahadoran, Z, Golzarand, M, Mirmiran, P, et al. (2013) The association of dietary phytochemical index and cardiometabolic risk factors in adults: Tehran Lipid and Glucose Study. J Hum Nutr Diet 26, Suppl. 1, 145153.
172. Jenkins, DJ, Kendall, CW, Banach, MS, et al. (2011) Nuts as a replacement for carbohydrates in the diabetic diet. Diabetes Care 34, 17061711.
173. Wu, L, Piotrowski, K, Rau, T, et al. (2014) Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism 63, 382391.
174. Tey, SL, Brown, RC, Chisholm, AW, et al. (2011) Effects of different forms of hazelnuts on blood lipids and α-tocopherol concentrations in mildly hypercholesterolemic individuals. Eur J Clin Nutr 65, 117124.
175. Zhang, X, Shu, XO, Gao, YT, et al. (2003) Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J Nutr 133, 28742878.
176. Nagata, C (2000) Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int J Epidemiol 29, 832836.
177. Kokubo, Y, Iso, H, Ishihara, J, et al. (2007) Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 116, 25532562.
178. Welty, FK, Lee, KS, Lew, NS, et al. (2007) Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. Arch Intern Med 167, 10601067.
179. Tabibi, H, Imani, H, Hedayati, M, et al. (2010) Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial. Perit Dial Int 30, 611618.
180. Back, HI, Kim, SR, Yang, JA, et al. (2011) Effects of Chungkookjang supplementation on obesity and atherosclerotic indices in overweight/obese subjects: a 12-week, randomized, double-blind, placebo-controlled clinical trial. J Med Food 14, 532537.
181. Hati, S, Vij, S, Singh, BP, et al. (2015) β-Glucosidase activity and bioconversion of isoflavones during fermentation of soymilk. J Sci Food Agric 95, 216220.
182. Tovar, J, Nilsson, A, Johansson, M, et al. (2014) Combining functional features of whole-grain barley and legumes for dietary reduction of cardiometabolic risk: a randomised cross-over intervention in mature women. Br J Nutr 111, 706714.
183. Giacco, R, Costabile, G, Della Pepa, G, et al. (2014) A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab Cardiovasc Dis 24, 837844.
184. Drouin-Chartier, JP, Gagnon, J, Labonte, ME, et al. (2015) Impact of milk consumption on cardiometabolic risk in postmenopausal women with abdominal obesity. Nutr J 14, 12.
185. Conway, V, Couture, P, Richard, C, et al. (2013) Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutr Metab Cardiovasc Dis 23, 12551262.
186. Gammon, CS, Kruger, R, Conlon, CA, et al. (2014) Inflammatory status modulates plasma lipid and inflammatory marker responses to kiwifruit consumption in hypercholesterolaemic men. Nutr Metab Cardiovasc Dis 24, 9199.
187. Shidfar, F, Froghifar, N, Vafa, M, et al. (2011) The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. Int J Food Sci Nutr 62, 289294.
188. Mahdavi-Roshan, M, Zahedmehr, A, Mohammad-Zadeh, A, et al. (2013) Effect of garlic powder tablet on carotid intima-media thickness in patients with coronary artery disease: a preliminary randomized controlled trial. Nutr Health 22, 143155.
189. Willett, WC, Sacks, F, Trichopoulou, A, et al. (1995) Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 61, 1402s1406s.
190. Sola, R, Fito, M, Estruch, R, et al. (2011) Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial. Atherosclerosis 218, 174180.
191. Defoort, C, Vincent-Baudry, S & Lairon, D (2011) Effects of 3-month Mediterranean-type diet on postprandial TAG and apolipoprotein B48 in the Medi-RIVAGE cohort. Public Health Nutr 14, 23022308.
192. Vincent-Baudry, S, Defoort, C, Gerber, M, et al. (2005) The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. Am J Clin Nutr 82, 964971.
193. Bedard, A, Riverin, M, Dodin, S, et al. (2012) Sex differences in the impact of the Mediterranean diet on cardiovascular risk profile. Br J Nutr 108, 14281434.
194. Richard, C, Couture, P, Desroches, S, et al. (2011) Effect of the Mediterranean diet with and without weight loss on cardiovascular risk factors in men with the metabolic syndrome. Nutr Metab Cardiovasc Dis 21, 628635.
195. Richard, C, Couture, P, Ooi, EM, et al. (2014) Effect of Mediterranean diet with and without weight loss on apolipoprotein B100 metabolism in men with metabolic syndrome. Arterioscler Thromb Vasc Biol 34, 433438.
196. Sotos-Prieto, M, Luben, R, Khaw, KT, et al. (2014) The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysis in the European Prospective Investigation into Cancer (EPIC)-Norfolk study. Br J Nutr 112, 122131.
197. Beltaifa, L, Chaouachi, A, Zerifi, R, et al. (2011) Walk–run transition speed training as an efficient exercise adjunct to dietary restriction in the management of obesity: a prospective intervention pilot study. Obes Facts 4, 4552.
198. Zhang, HJ, Han, P, Sun, SY, et al. (2013) Attenuated associations between increasing BMI and unfavorable lipid profiles in Chinese Buddhist vegetarians. Asia Pac J Clin Nutr 22, 249256.
199. Bradbury, KE, Crowe, FL, Appleby, PN, et al. (2014) Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans. Eur J Clin Nutr 68, 178183.
200. Karelis, AD, Fex, A, Filion, ME, et al. (2010) Comparison of sex hormonal and metabolic profiles between omnivores and vegetarians in pre- and post-menopausal women. Br J Nutr 104, 222226.
201. Maiyoh, GK, Kuh, JE, Casaschi, A, et al. (2007) Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells. J Nutr 137, 21852189.
202. Olsen, A, Egeberg, R, Halkjaer, J, et al. (2011) Healthy aspects of the Nordic diet are related to lower total mortality. J Nutr 141, 639644.
203. Adamsson, V, Reumark, A, Fredriksson, IB, et al. (2011) Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). J Intern Med 269, 150159.
204. Uusitupa, M, Hermansen, K, Savolainen, MJ, et al. (2013) Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome – a randomized study (SYSDIET). J Intern Med 274, 5266.
205. Hodson, L, Harnden, KE, Roberts, R, et al. (2010) Does the DASH diet lower blood pressure by altering peripheral vascular function? J Hum Hypertens 24, 312319.
206. Krikken, JA, Dallinga-Thie, GM, Navis, G, et al. (2012) Short term dietary sodium restriction decreases HDL cholesterol, apolipoprotein A-I and high molecular weight adiponectin in healthy young men: relationships with renal hemodynamics and RAAS activation. Nutr Metab Cardiovasc Dis 22, 3541.
207. Frassetto, LA, Schloetter, M, Mietus-Synder, M, et al. (2009) Metabolic and physiologic improvements from consuming a Paleolithic, hunter–gatherer type diet. Eur J Clin Nutr 63, 947955.
208. Ryberg, M, Sandberg, S, Mellberg, C, et al. (2013) A Palaeolithic-type diet causes strong tissue-specific effects on ectopic fat deposition in obese postmenopausal women. J Intern Med 274, 6776.

Keywords

Nutritional management of hyperapoB

  • Valérie Lamantia (a1) (a2) (a3), Allan Sniderman (a4) and May Faraj (a1) (a2) (a3)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed